Literature DB >> 2711294

Temporary elevation of CA 125 after abdominal surgical treatment for benign disease and cancer.

R W Talbot1, D J Jacobsen, D M Nagorney, G D Malkasian, R E Ritts.   

Abstract

Analyses of preoperative and one to seven day postoperative determinations of CA 19-9, carcinoembryonic antigen (CEA) and CA 125 levels in 873 patients indicate that postoperative CA 19-9 and CEA serum levels were within the expected technical variance of the preoperative assay values in patients who were considered to have negative findings (below the reference value) from these tests preoperatively. If the test results were preoperatively positive in patients with cancer, they decreased postoperatively to or below normal reference values, unless the operation was palliative and significant tumor removal was not possible. For patients with a preoperative positive CA 125 level (greater than 35 units per mililiter), the postoperative serum levels were comparable with the CEA and CA 19-9 result. However, when the preoperative CA 125 level was within normal limits, 62 per cent of the patients had postoperative elevations, often to levels of less than 35 units per milliliter. Sequential postoperative determinations of CA 125 in 21 patients revealed that maximum levels of CA 125 were seen about two to four hours after the operation and that elevations persisted for as long as three months. Inferential evidence suggests that postoperative increases in serum CA 125 occur from incision and healing of the peritoneum and omentum by de novo synthesis of this antigen rather than shedding from tissues. Patients with CA 125 negative results and with carcinoma of the ovary having postoperative increases of this antigen within two months of the operation may pose a difficult problem in interpretations, and such patients require further investigation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2711294

Source DB:  PubMed          Journal:  Surg Gynecol Obstet        ISSN: 0039-6087


  11 in total

Review 1.  Prognostic and predictive value of CA-125 in the primary treatment of epithelial ovarian cancer: potentials and pitfalls.

Authors:  Iván Díaz-Padilla; Albiruni Ryan Abdul Razak; Lucas Minig; Marcus Q Bernardini; Josep María Del Campo
Journal:  Clin Transl Oncol       Date:  2012-01       Impact factor: 3.405

2.  The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: a gynecologic Oncology Group study.

Authors:  Amanda Nickles Fader; James Java; Thomas C Krivak; Robert E Bristow; Ana I Tergas; Michael A Bookman; Deborah K Armstrong; Edward J Tanner; David M Gershenson
Journal:  Gynecol Oncol       Date:  2013-12-13       Impact factor: 5.482

3.  Increased CA 125 in tuberculous peritonitis.

Authors:  J Collazos
Journal:  Gut       Date:  1995-08       Impact factor: 23.059

4.  CA 125 secretion by peritoneal mesothelial cells.

Authors:  A M Zeillemaker; H A Verbrugh; A A Hoynck van Papendrecht; P Leguit
Journal:  J Clin Pathol       Date:  1994-03       Impact factor: 3.411

5.  Peri- and postoperative changes in serum levels of four tumor markers and three acute phase reactants in benign and malignant gynecological diseases.

Authors:  E Avall-Lundqvist; K Sjövall; L O Hansson; P Eneroth
Journal:  Arch Gynecol Obstet       Date:  1992       Impact factor: 2.344

6.  Significance of postoperative CA-125 decline after cytoreductive surgery in stage IIIC/IV ovarian cancer.

Authors:  Seung-Chul Yoo; Jong-Hyuck Yoon; Mi-Ok Lyu; Woo Young Kim; Suk-Joon Chang; Ki-Hong Chang; Hee-Sug Ryu
Journal:  J Gynecol Oncol       Date:  2008-09-30       Impact factor: 4.401

7.  The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group study.

Authors:  Kristin K Zorn; Chunqiao Tian; William P McGuire; William J Hoskins; Maurie Markman; Franco M Muggia; Peter G Rose; Robert F Ozols; David Spriggs; Deborah K Armstrong
Journal:  Cancer       Date:  2009-03-01       Impact factor: 6.860

8.  Photoimmunotherapy and biodistribution with an OC125-chlorin immunoconjugate in an in vivo murine ovarian cancer model.

Authors:  B A Goff; U Hermanto; J Rumbaugh; J Blake; M Bamberg; T Hasan
Journal:  Br J Cancer       Date:  1994-09       Impact factor: 7.640

9.  Clinical significance of serum CA-125 in Korean females with ascites.

Authors:  So Young Bae; Jun Haeng Lee; Jun Young Park; Da-min Kim; Byung-Hoon Min; Poong-Lyul Rhee; Jae J Kim
Journal:  Yonsei Med J       Date:  2013-09       Impact factor: 2.759

10.  Perioperative changes in serum CA125 levels: a prognostic factor for disease-specific survival in patients with ovarian cancer.

Authors:  Nienke Zwakman; Rafli van de Laar; Toon Van Gorp; Petra L M Zusterzeel; Marc P M L Snijders; Isabel Ferreira; Leon F A G Massuger; Roy F P M Kruitwagen
Journal:  J Gynecol Oncol       Date:  2016-09-12       Impact factor: 4.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.